Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Dr_Dan  – Germany, 2020-02-11 16:20 (864 d 23:10 ago) – Posting: # 21159
Views: 1,649

Dear qualityassurance
In case of a bioequivalence study, it also depends on whether the concomitant medication was
given obligatory to all subjects or was taken accidentally by one or maybe more subjects. In the first case, the effect for the test and the reference formulation would be the same and you do not need to argue. Otherwise, a detailed risk analysis should be carried out, which describes the estimated PK effects of the concomitant medication on the bioequivalence decision. If only a view subjects are affected a sensitivity analysis could be carried out.
I hope this helps.

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
22,166 posts in 4,645 threads, 1,572 registered users;
online 5 (0 registered, 5 guests [including 3 identified bots]).
Forum time: Saturday 16:31 CEST (Europe/Vienna)

Absolute certainty is a privilege of uneducated minds  and fanatics.
It is, for scientific folk, an unattainable ideal.    Cassius J. Keyser

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5